Dingdang Health Technology Group Ltd. disclosed that it bought back 94,500 ordinary shares on 4 June 2026 through on-market transactions at HK$0.84–0.85 per share, spending HK$0.08 million in aggregate.

Including this latest tranche, the company has repurchased 71.59 million shares since the current mandate was approved on 28 May 2025, utilising 5.43 % of the 1.32 billion shares then in issue. The board is authorised to repurchase up to 131.95 million shares under the mandate.

Repurchases conducted between 19 May and 4 June 2026 total 6.77 million shares—about 0.54 % of the existing 1.25 billion issued shares—and are pending formal cancellation.

Following the 4 June transaction, Dingdang Health’s issued share capital remains unchanged at 1.25 billion shares; the company holds no treasury shares. In accordance with Main Board Rule 10.06(3)(a), the issuer is restricted from announcing or carrying out any new equity issuance until 4 July 2026.

All repurchases were executed in compliance with Hong Kong Stock Exchange regulations and the explanatory statement dated 30 April 2025.